Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

Our Mission

Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from rare diseases by developing safe and efficacious therapies that will dramatically enhance their quality of life. We focus on developing therapies that specifically target the root cause of the disease. The Palvella team is committed to recruiting passionate and like-minded collaborators to ensure we expeditiously deliver on this important mission for rare disease patients.

Many Unmet Needs in Rare Genodermatoses

Of the almost 600 rare dermatologic diseases identified, less than 2 percent have an approved therapy. Because many of these diseases are genetic, those suffering from these rare skin diseases endure lifelong symptoms – often severe debilitation and chronic pain. Further, the multitude of research in recent years in this area has elucidated the mechanisms of many of the diseases, bringing treatment approaches within reach. We are proud to lead the way for a new era in the advancement of therapies for serious rare genodermatoses.

Wes Kaupinen Headshot

Wes Kaupinen

President and CEO

Wes Kaupinen

Wes Kaupinen

President and CEO

Mr. Kaupinen brings more than 17 years of experience as an operating executive and early stage investor.
Mr. Kaupinen brings more than 17 years of entrepreneurial life sciences experience as an operating executive and early stage investor, including having worked closely with several companies that have secured FDA approvals of novel treatments for high unmet indications. Prior to Palvella, Mr. Kaupinen served as Senior Vice President of Corporate Development and Commercialization at Insmed (NASDAQ: INSM), a global commercial stage biopharmaceutical company focused on rare diseases. Previously, Mr. Kaupinen was a Principal at Quaker Partners, a life sciences venture capital firm with $700mm under management, where he worked on several public and private investments, including recruiting new leadership to Insmed to execute on a rare disease strategy. Mr. Kaupinen has served as a board director or observer for more than ten companies, including leading Series A investments in Intact Vascular (backed by NEA, HIG, and Quaker) and TELA Bio (NASDAQ: TELA). Mr. Kaupinen earned an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. in Economics from The University of Virginia.

LinkedIn

Braham Shroot Headshot

Braham Shroot, Ph.D.

Chief Scientific Officer

Braham Shroot, Ph.D.

Braham Shroot, Ph.D.

Chief Scientific Officer

Dr. Shroot brings over 30 years of experience in drug research and development specializing in skin disorders, and played a key role in the development of commercially available therapeutics including Differin, Atralin, Vectical, and Diflucan.
Dr. Shroot is the recipient of the American Skin Association’s Lifetime Achievement Award and an honorary lifetime member of the Society for Investigative Dermatology. Prior to Palvella, Dr. Shroot held senior roles in the biopharma industry, including President of Galderma Research, Chief Scientific Officer of Barrier Therapeutics (sold to Stiefel), and CSO/VP of R&D for DFB Pharmaceuticals. Dr. Shroot also served as the chief executive officer of Signum Biosciences, a company developing dermatological therapeutics. Dr. Shroot is an inventor on over 50 patents, author of over 260 publications, and a member of the editorial boards of several prestigious dermatology journals. Dr. Shroot earned a B.Sc. in Chemistry and a Ph.D. in Organic Chemistry from Glasgow University in Scotland.

LinkedIn

Kathy Goin Headshot

Kathy Goin

VP of Development Operations

Kathy Goin

Kathy Goin

VP of Development Operations

With a positive and relentless spirit, Ms. Goin builds and coaches high performing and successful clinical development teams.
Since 1998, Ms. Goin served many patient populations by developing drugs and devices to treat different cancers, heart disease/abnormalities, and pain conditions. As Vice President, Clinical Operations at Trevena, Inc., she shaped trial execution strategies across all programs by promoting meaningful and streamlined interactions between sites and sponsor representatives and employing modern processes for lean yet highly effective trial execution. These approaches led to helping the company start and finish three Phase III studies in just under two years. In 2017, she joined colleagues to start Clinical Works, a progressive specialty consulting firm focused on helping emerging and small biotech/pharmaceutical companies start their clinical programs and execute trials. Ms. Goin holds a Master of Science in Occupational Therapy from College Misericordia.

LinkedIn

Emily Cook Headshot

Emily Cook

VP of Clinical Operations

Emily Cook

Emily Cook

VP of Clinical Operations

Ms. Cook’s 15-year career spans large and small pharmaceutical companies where she has managed clinical development programs for clinical and commercial stage products.

Prior to Palvella, Ms. Cook served as Director of Clinical Operations for Complexa, a clinical stage biopharmaceutical company focused on life-threatening fibrosis and inflammatory diseases. Prior to joining Complexa, she served as the director of clinical operations for Trevena, Inc., where she contributed to the completion of multiple Phase 1 through Phase 3 clinical trials. Emily also held clinical and sales roles at Applied Clinical Intelligence, Yaupon Therapeutics, and Sanofi-Aventis Pharmaceuticals. Emily received her B.A. in Microbiology from Miami University and earned her Clinical Research Associate certification from the Association of Clinical Research Professionals.

LinkedIn

Kathleen McGowan Headshot

Kathleen McGowan

Chief Financial Officer

Kathleen McGowan

Kathleen McGowan

Chief Financial Officer

Ms. McGowan brings over 35 years of diversified financial experience in the pharmaceutical and biotech industry.
Before Palvella, Ms. McGowan served as Chief Financial Officer of VaxInnate, a private company developing vaccines for influenza, malaria, and dengue. Prior to VaxInnate, she led financial operations at Tobira Therapeutics (acquired by Allergan plc), a clinical-stage company developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. Earlier in her career, Ms. McGowan held financial senior management roles at Discovery Laboratories, Inc. (now Windtree Therapeutics), Claneil Enterprises, Liposome Company (acquired by Elan Corp.), and Johnson & Johnson. She received her B.S. in finance and accounting from Drexel University and holds an M.B.A. in finance from Fairleigh Dickinson University.

LinkedIn

Jason Connor, Ph.D.

VP of Clinical and Biostatistics

Jason Connor, Ph.D.

Jason Connor, Ph.D.

VP of Clinical and Biostatistics

Prior to joining the Palvella team, Dr. Connor founded ConfluenceStat, a statistical consulting firm working with biotech and biotech investors. He is also Assistant Professor of Medical Education at the University of Central Florida College of Medicine (since 2008) and Visiting Professor at Johns Hopkins School of Public Health, teaching a summer class on Bayesian Adaptive Trials (since 2010). Prior to founding ConfluenceStat, he was on the senior team at Berry Consultants, the worldwide leader in innovative and Bayesian adaptive trial design, leading a team of biostatisticians and collaborating on over 200 Bayesian adaptive trials, and was an internal consultant at Cleveland Clinic. Jason received his Ph.D. jointly in Statistics & Public Policy from Carnegie Mellon University and his B.S. in Biomedical Engineering from Texas A&M University. He has co-authored over 90 papers in the statistics and clinical literature.

Greg Coulter Headshot

Greg Coulter, Ph.D.

VP of Technical Operations

Greg Coulter, Ph.D.

Greg Coulter, Ph.D.

VP of Technical Operations

Dr. Greg Coulter brings to Palvella deep expertise in drug substance characterization, drug product formulation, scale-up and GMP manufacturing from clinical to commercial stages.
Prior to Palvella, Dr. Coulter served as president of CTM Solutions, a manufacturing and clinical supplies consultancy for early and development stage companies. Prior to CTM Solutions, Dr. Coulter led the Formulations and Analytical Services department for a prominent international contract research organization and managed all GMP manufacturing for a Seattle biopharmaceutical company. Dr. Coulter earned his Bachelor of Science (Hons) in Biochemistry from Bishop’s University in Lennoxville, Canada, followed by a Ph.D. in Biological Chemistry and a Master of Science in Organic Chemistry from the University of Guelph in Guelph, Canada.

LinkedIn

Stephen Yoo Headshot

Stephen Yoo, MD

Senior Clinical Advisor

Stephen Yoo, MD

Stephen Yoo, MD

Senior Clinical Advisor

Dr. Yoo brings deep expertise in rare diseases and serious skin disorders from his clinical training and practice as a dermatologist and as a senior executive in drug development.

Dr. Yoo currently serves as chief medical officer of a newly incubated company focusing on allergic mediated diseases while working as an entrepreneur in residence with Atlas Ventures. Previously he was the first CMO of REGENXBIO, a leading publicly traded clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. While at REGENXBIO he helped to advance a pipeline focusing on developing AAV gene therapies for retinal, metabolic and neurodegenerative diseases, many of which were rare. Prior to joining REGENXBIO, Dr. Yoo served as medical science director of clinical development and group director of clinical development at AstraZeneca. In previous roles at MedImmune, he provided strategic clinical leadership for early phase programs. Dr. Yoo led early and late-phase clinical trials for both common and rare autoimmune diseases. Prior to MedImmune, Dr. Yoo served as associate director of clinical development at Abbott Laboratories.

Dr. Yoo earned a B.A. in molecular and cell biology from the University of California, Berkeley and an M.D. from the UCLA School of Medicine. He has served as a member of the board of directors (resident member) for the Society for Investigative Dermatology.

Roger L. Kaspar, Ph.D.

Scientific Advisor

Roger L. Kaspar, Ph.D.

Roger L. Kaspar, Ph.D.

Scientific Advisor

Dr. Kaspar is the founder and Chief Scientific Officer of Ayni Therapeutics, a company focused on developing novel RNA therapeutics, including inhibitors based on RNA interference (RNAi) technology, for skin disorders. Dr. Kaspar received his doctorate from the University of Washington in biochemistry and performed post-doctoral work at M.I.T., Stanford University, and Chiba University. After serving on the faculty at Brigham Young University in the Department of Chemistry and Biochemistry, he left academia to work at SomaGenics, a biotech company focused on developing RNA-centered therapeutics and research tools. Dr. Kaspar subsequently founded TransDerm (acquired by Allergan), DeScent Technologies, and most recently Ayni Therapeutics. Drawing on his expertise in post-transcriptional gene regulation, his current efforts are focused on designing highly potent and selective therapeutic siRNAs that target disease-causing genes for dermatological applications, developing topical formulations to locally deliver therapeutics, and using non-invasive intravital imaging to monitor functional delivery.

George Jenkins

Chairman

George Jenkins

Chairman

From 1987 to 2005, Mr. Jenkins was a general partner of Apax Partners, a leading global private equity firm where he served as chief operating officer overseeing a multi-billion dollar venture capital and private equity investment portfolio. Since 2006, Mr. Jenkins has been an active private investor primarily funding technology-based start-ups. Mr. Jenkins has been or currently serves as a board member of numerous public and private companies, including SkinMedica (acquired by Allergan), Colorescience, Flower Orthopedics, Power Survey, Sunglass Hut, and Spyder Active Sports. Prior to joining Apax, Mr. Jenkins was a banker managing banking facilities in Europe. Mr. Jenkins earned a B.A. in Economics and Accounting from Lafayette College where he currently serves as a Trustee.

LinkedIn

Todd Davis

Director

Todd Davis

Director

Mr. Davis is a founding Managing Director at HealthCare Royalty Partners, a global healthcare investment firm. He has thirty years of experience working in and investing in the pharmaceutical and biotechnology industries. Over the course of his career, Mr. Davis has been involved in over $2 billion in healthcare deals and nearly $1 billion in royalty financings. He has also led, structured and closed over 40 additional intellectual property licenses, as well as growth equity, and debt deals. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Prior to beginning his principal investment career in 2001, Mr. Davis held various sales and product management roles at Abbott Laboratories and worked in business development, operations and licensing at Elan Pharmaceuticals. Mr. Davis holds a B.S. from the U.S. Naval Academy and an M.B.A. from Harvard University. He currently serves on the board of Ligand Pharmaceuticals (NASDAQ: LGND).

LinkedIn

John Doux, M.D., FAAD

Director

John Doux, M.D., FAAD

Director

Dr. Doux joined Palo Alto Investors, a healthcare-focused investment firm, in 2004 as an analyst. Dr. Doux is a board certified dermatologist who maintained a clinical practice in medical and surgical dermatology for seventeen years. He earned his M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing and publishing research in the laboratory of Dr. David Woodley. He completed training at Brigham and Women’s Hospital and Stanford Medical Center and earned an M.B.A. at the Wharton School of Business where he was a Palmer Scholar.

Cory Freedland

Director

Cory Freedland

Director

Cory S. Freedland joined Samsara in 2017. Prior to Samsara, Cory was a Principal at Sofinnova Ventures where he focused on biopharmaceutical investments. Cory played a central role in Sofinnova’s investments in Civitas (acquired by Acorda), NextCure, NuCana Biomed (NCNA), Principia Biopharma, Spark Therapeutics (ONCE), Ziarco (acquired by Novartis), and ZS Pharma (ZSPH; acquired by AstraZeneca). Prior to Sofinnova, Cory was a Principal at Novo A/S. Before his transition to healthcare investing, he was a Vice President in the healthcare investment banking practice at Morgan Stanley. Prior to transitioning to life sciences finance, Cory worked as a research scientist for Roche focusing on preclinical drug discovery and novel target identification for psychiatric and neurodegenerative diseases. He received his PhD in Pharmacology from Wake Forest University School of Medicine and his MBA from the Kellogg School of Management.  Cory holds a BA in Psychology and Religious Studies from Connecticut College.

LinkedIn

Elaine J. Heron, Ph.D.

Director

Elaine J. Heron, Ph.D.

Director

Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, a clinical stage drug development company from February 2009 until October 2015, and she continues to serve as board member. She also serves as a board member of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a therapeutics company with annual sales over $1 billion, and Vala Sciences, a private biotechnology tools company. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology tools company. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology tools company, including the positions of general manager and VP of sales and marketing. Dr. Heron earned a B.S. in Chemistry with highest distinction, a Ph.D. in Analytical Biochemistry from Purdue University, and an M.B.A. from Pepperdine University.

LinkedIn

Scott Morenstein

Director

Scott Morenstein

Director

Scott Morenstein is a Managing Director and Portfolio Manager at CAM Capital, where he has led the firm’s investment strategy in both private and public life sciences companies since 2013. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011. Prior to joining CAM Capital in 2013, Mr. Morenstein was a Partner at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, life sciences focused venture capital firms affiliated with Caxton Associates, which he joined in 2007.

Prior to joining Caxton Advantage, Mr. Morenstein was an investment banker and research analyst at Seaview Securities and Lehman Brothers from 2000-2005. Mr. Morenstein served as a director and CAM was the largest investor in Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals. He was nominated a director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X’s board of directors until its acquisition by Cephalon. He currently serves as a director of Molecular Templates (Nasdaq: MTEM), Antios Therapeutics, Primmune Therapeutics, and Velicept Therapeutics.

LinkedIn

Wes Kaupinen

President and CEO

Wes Kaupinen

President and CEO

Mr. Kaupinen brings more than 17 years of experience as an operating executive and early stage investor.
Mr. Kaupinen brings more than 17 years of entrepreneurial life sciences experience as an operating executive and early stage investor, including having worked closely with several companies that have secured FDA approvals of novel treatments for high unmet indications. Prior to Palvella, Mr. Kaupinen served as Senior Vice President of Corporate Development and Commercialization at Insmed (NASDAQ: INSM), a global commercial stage biopharmaceutical company focused on rare diseases. Previously, Mr. Kaupinen was a Principal at Quaker Partners, a life sciences venture capital firm with $700mm under management, where he worked on several public and private investments, including recruiting new leadership to Insmed to execute on a rare disease strategy. Mr. Kaupinen has served as a board director or observer for more than ten companies, including leading Series A investments in Intact Vascular (backed by NEA, HIG, and Quaker) and TELA Bio (NASDAQ: TELA). Mr. Kaupinen earned an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.A. in Economics from The University of Virginia.

LinkedIn

Michael Murray

Observer

Michael Murray

Observer

Mr. Murray joined BVF Partners L.P. in 2013. Prior to joining the General Partner, Mr. Murray was an Associate at Leerink Swann in the strategy consulting division where he advised pharmaceutical and biotech clients on M&A strategy, due diligence, clinical development strategy, and commercial opportunity assessments. He holds an A.B. in Human Evolutionary Biology and a Secondary Field in Economics from Harvard College.

LinkedIn